Physician profile
Joel Spellun
NPI 1295785251
$2,111.54
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $589 · 2021: $165.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $654.36 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $324.59 | 2019-2021 | |
| Janssen Biotech, INC. | $291.04 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $166.49 | 2019-2020 | |
| Pfizer INC. | $107.59 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $94.49 | 2019 | |
| Allergan, INC. | $88.18 | 2019 | |
| Braintree Laboratories, INC. | $63.43 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $50.16 | 2019-2020 | |
| Gilead Sciences, INC. | $48.63 | 2019-2020 | |
| Amgen INC. | $34.86 | 2020 | |
| Alfasigma USA, INC. | $29.70 | 2020 | |
| Ucb, INC. | $25.64 | 2019 | |
| Intercept Pharmaceuticals, INC. | $23.45 | 2020 | |
| Redhill Biopharma INC. | $22.84 | 2020 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $18.62 | 2019 | |
| Amag Pharmaceuticals, INC. | $18.15 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $18.09 | 2019 | |
| Daiichi Sankyo INC. | $15.85 | 2020 | |
| Celgene Corporation | $15.38 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joel Spellun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.